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Cyclophilin A promotes HIV-1 reverse transcription
but its effect on transduction correlates best with
its effect on nuclear entry of viral cDNA
Alberto De Iaco1 and Jeremy Luban1,2*
Abstract
Background: The human peptidyl-prolyl isomerase Cyclophilin A (CypA) binds HIV-1 capsid (CA) and influences
early steps in the HIV-1 replication cycle. The mechanism by which CypA regulates HIV-1 transduction efficiency is
unknown. Disruption of CypA binding to CA, either by genetic means or by the competitive inhibitor cyclosporine
A (CsA), reduces the efficiency of HIV-1 transduction in some cells but not in others. Transduction of certain cell
types increases significantly when CypA binding to particular HIV-1 CA mutants, i.e., A92E, is prevented. Previous
studies have suggested that this cell type-specific effect is due to a dominant-acting, CypA-dependent restriction
factor.
Results: Here we investigated the mechanism by which CypA regulates HIV-1 transduction efficiency using 27
different human cell lines, 32 HeLa subclones, and several previously characterized HIV-1 CA mutants. Disruption of
CypA binding to wild-type CA, or to any of the mutant CAs, caused a decrease in HIV-1 reverse transcription in all
the cell lines analyzed here. This block to reverse transcription, though, did not correlate with cell type-specific
effects on transduction efficiency. The level of 2-LTR circles, a marker for nuclear transport of the viral cDNA that
results from reverse transcription, correlated closely with effects on infectivity. No correlation was observed
between the cell type-specific effects on infectivity and the steady-state CypA protein levels in these cells. Instead,
as indicated by a fate-of-capsid assay, CsA released the HIV-1 CA core from an apparent state of hyperstabilization,
in a cell type-specific manner.
Conclusion: These data demonstrate that, while CypA promotes reverse transcription under all conditions tested
here, its effect on HIV-1 infectivity correlates more closely with effects on nuclear entry of the viral cDNA. The data
also support the hypothesis that a cell-type specific CypA-dependent restriction factor blocks HIV-1 replication by
delaying CA core uncoating and hindering nuclear entry.
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Background
The peptidyl-prolyl isomerase cyclophilin A (CypA) modu-
lates human immunodeficiency virus type 1 (HIV-1) repli-
cation. The HIV-1 Gag precursor polyprotein (Pr55gag)
associates with CypA during virion assembly and incorpo-
rates the host isomerase into nascent viral particles [1-5].
The CypA binding site maps to the capsid (CA) domain of
Pr55gag, in particular to CA residues glycine 89 and proline
90 located in an exposed, proline-rich loop [1,3,6,7]. CypA
also interacts with mature HIV-1 cores [3,7]. Though CypA
catalyzes the isomerization of CA proline 90 in vitro, it is
not clear if this isomerase activity of CypA is required for
the modulation of HIV-1 replication, or if simple inter-
action with CA is sufficient [8-10].
The relevance of the CA-CypA interaction for HIV-1
replication has been demonstrated using multiple ex-
perimental approaches, including disruption of binding
with the competitive inhibitor cyclosporine A (CsA), CA
mutants G89V and P90A, CypA mutants in the active
site, and depletion of endogenous CypA by gene knock-
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out or RNA knock-down [11-14]. The conclusions from
experiments using each of these methods are in agree-
ment with each other.
CypA binding to HIV-1 CA promotes an early step in
the HIV-1 replication cycle in specific target cells, in-
cluding MT4, CEM, 293 T, HOS, TE671, Jurkat T cells,
and primary human CD4+ T cells [11,15-20]. HIV-1 rep-
lication in other target cells, including HeLa and H9 T
cells, is independent of CypA [12,15]. Serial passage of
HIV-1 in CD4+-HeLa cells, in the presence of a competi-
tive inhibitor of the CA-CypA interaction, selected for
HIV-1 CA mutants A92E and G94D [21]. HIV-1 viruses
bearing either the A92E or G94D CA mutation are
defective for replication in HeLa or H9 T cells, but dis-
ruption of the CypA-CA interaction rescued infectivity
of these mutants in these cells [12,15,16,19]. Interest-
ingly, CA mutations N74D and A105T have no effect on
the CA-CypA interaction, but, when encoded in cis, either
mutant will rescue the infectivity defect of the A92E mutant
[22-26]. In addition, N74D and A105T render WT HIV-1
dependent on CypA-CA binding in H9 and HeLa cells,
host cells that do not otherwise require CypA for WT
HIV-1 replication [24,27]. When infecting 293 T, HOS,
TE671, or Jurkat T cells, A92E and G94D render HIV-1
replication independent of CypA [12,16,17,19,28].
How CypA promotes HIV-1 infection or contributes
to the block to A92E or G94D mutant virus replication
in certain cell lines is not well understood. More specif-
ically, it is not clear at which step of HIV-1 replication
CypA inhibits A92E and G94D mutant viruses. Some
groups have shown that the replication block is before
completion of reverse transcription [16,29], but others
have shown that it acts during later steps [17,30]. Some
groups propose that CypA modulates HIV-1 CA core
disassembly and the level of CypA expression in the tar-
get cell determines the proper timing of the process
[15,17,19,29,31]. However, others were unable to confirm
this [16,18]. Some experiments suggest that CypA is in-
volved in the selection of the nuclear entry pathway of
the virus [32]. Finally, heterokaryon experiments re-
vealed a dominant, CypA-dependent restriction activity
in HeLa cells [16]. Here we revisit the role of the CypA-
CA interaction on HIV-1 replication, exploiting a large
panel of different cell lines, select CA mutants, and an
improved assay for HIV-1 nuclear entry that distin-
guishes 2-LTR circles from autointegrants [26].
Results
Cell-type specific effects of CsA on HIV-1 transduction
correlate more closely with CypA KD than do CA mutants
that block CypA binding
The CypA-CA interaction can be disrupted with the com-
petitive inhibitor CsA or by mutation of CA amino acids
important for binding [1,3]. Before assessing a large panel
of cell lines for the cell type-specific effects of CypA on
HIV-1 transduction the effect of CsA or of CypA-binding
loop mutants was compared to the effect of CypA KD in
HeLa and Jurkat, two cell lines previously shown to have
very different CypA phenotypes [12,15].
HeLa and Jurkat cells were transduced with lentiviral
KD vectors that encode miRNAs engineered to knock-
down either CypA mRNA or firefly luciferase control, as
previously described [8,12,23,33]. The primary tran-
script containing the miRNA also encodes puromycin
N-acetyltransferase, so transduced cells were selected
in pools in the presence of puromycin. The two stable KD
cell lines were challenged with VSV G-pseudotyped, three-
part HIV-1-GFP reporter vectors bearing either wild-type
CA or the A92E CA mutation. These and all virus stocks
used here were normalized by reverse transcriptase activity.
72 hrs after transduction GFP expression was assessed
by flow cytometry as a measure of transduction effi-
ciency (Figure 1A). As a control that GFP reporter activ-
ity resulted from infection and not from passive transfer
of GFP protein, target cells were also challenged with an
HIV-1 vector bearing two RT mutations (D185K and
D186K) that render the viral polymerase catalytically in-
active (data not shown). As previously reported, CypA
KD inhibited WT CA transduction in Jurkat about 2-
fold, but there was no inhibition of WT vector in HeLa
cells [8,12,17]. In contrast, the A92E CA mutant virus
was 3-fold lower than WT CA in the control HeLa cells,
while depletion of CypA increased its transduction
around 10-fold. In Jurkat T cells, CypA KD had no effect
on A92E virus replication.
The effect of 5 μM CsA on WT and A92E CA mutant
transduction of HeLa and Jurkat T cells was tested next
(Figure 1B). In each condition, when the target cells
were incubated in CsA the effect was identical to that
observed with CypA KD. The effect of CA mutants
G89V and P90A was tested next (Figure 1C). G89V
inhibited transduction around 10-fold in both cell lines
and, when combined with A92E, transduction was res-
cued in HeLa cells but not Jurkat. P90A inhibited trans-
duction of Jurkat T cells, but there was no effect in
HeLa. Combination with A92E rescued P90A transduc-
tion in both cell lines. This analysis clearly shows that
P90A and G89V CA mutations have pleiotropic effects,
inhibiting HIV-1 transduction to a greater extent than
simple disruption of the CypA/CA interaction. In light
of these results, CsA was used in the subsequent experi-
ments examining the CA/CypA interaction in a panel of
cell lines.
CypA interaction with HIV-1 CA universally promotes
reverse transcription
Using PCR primers that detect full-length viral cDNA
(Figure 2A) several groups have reported that CypA
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promotes HIV-1 infectivity at a stage in the replication
cycle before the completion of reverse transcription
[11,16,17,29]. In contrast, disagreement exists among
different labs regarding which step in the viral replica-
tion cycle is inhibited by CypA interaction with the
A92E or G94D mutant CAs [16,17,29]. Recently, to
clarify the role of TNPO3 in HIV-1 nuclear entry, we de-
veloped a PCR assay that is specific for the 2-LTR circles
that form when the viral cDNA enters the nucleus [34].
Unlike PCR primers that are commonly used to detect
2-LTRs [35], these primers hybridize directly to the
LTR-LTR junction (Figure 1B), and therefore distinguish
bona fide 2-LTR circles from autointegrants [23,26].
To understand the role of CypA in HIV-1 replication,
we examined the effect of CsA on HIV-1 infectivity,
reverse transcription, and nuclear entry (Figure 3). HeLa
and Jurkat T cells were treated with 5 μM CsA or
DMSO as control, and challenged with WT, A92E,
A105T or A92E/A105T CA mutant viruses (Figure 3).
A105T and A92E/A105T CA mutants were included in
the analysis because they confer sensitivity to CsA in H9
cells [27]. D185K/D186K RT double mutant virus was
used as a control to demonstrate that signal in the PCR
reactions required de novo viral cDNA synthesis in the
target cells and did not result from contaminating DNA.
In each case, the PCR products with the RT mutant
were at least 100-fold lower than for the wild-type virus
(data not shown).
As a measure of infectivity, GFP expression from
the reporter gene was assessed 72 hrs after infection
(Figure 3A). CsA had no effect on WT HIV-1 transduc-
tion of HeLa cells but inhibited transduction of Jurkat T
cells 2-fold. The infectivity of HIV-1 bearing the CA
A92E mutation was increased 11-fold in HeLa cells. In
Jurkat T cells, the A92E mutant conferred resistance to
the inhibitory effect of CsA. The CA A105T mutant
Figure 1 Effects of CsA on HIV-1 transduction correlate more closely with CypA KD than do CA mutants that block CypA binding.
HeLa cells (left) or Jurkat cells (right) were challenged with HIV-1 GFP reporter viruses bearing wild-type (WT) or mutant CA. 72 hours later GFP
expression was assessed by flow cytometry. The cells were (A) depleted of endogenous CypA or (B) pre-treated with 5 μM CsA or DMSO and
challenged with WT or A92E CA mutant virus. (C) Cells were challenged with viruses bearing the indicated capsid mutations (P90A, G89V, P90A/
A92E, G89V/A92E). Data represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
De Iaco and Luban Retrovirology 2014, 11:11 Page 3 of 15
http://www.retrovirology.com/content/11/1/11
virus replicated like the WT in HeLa cells and was
inhibited 2-fold in the presence of CsA. On Jurkat T
cells, the A105T mutant was less infectious than the
WT, but the magnitude inhibition by CsA was similar to
that of the WT. When combined in cis, the A105T mu-
tant rescued infectivity of the A92E mutant virus in
HeLa cells, but conferred sensitivity to CsA. CA mutant
A105T therefore seems to have a dominant effect over
the A92E mutation.
The effect of CsA on the efficiency of reverse tran-
scription (Figure 2A) by WT, A92E, A105T, and A92E/
A105T CA mutant viruses was assessed acutely after
infection of HeLa and Jurkat T cells (Figure 3B).
Interestingly, CsA caused a modest reverse transcrip-
tion defect of similar magnitude for all the viruses, in
both HeLa and Jurkat T cells. Inhibition of HIV-1 re-
verse transcription by CsA correlated with effects on
infectivity of WT virus in Jurkat T cells and for A105T
and A92E/A105T mutant viruses infecting either HeLa
or Jurkat (compare Figure 3A and B). In contrast, the
inhibition of reverse transcription by CsA did not
correlate with the infectivity effects for WT CA in
HeLa cells or for A92E infecting either HeLa or Jurkat
T cells. In all cases then, CA interaction with CypA
increased the level of reverse transcription.
The CypA-CA interaction inhibits HIV-1 nuclear entry in a
cell specific manner
Given the discrepancy between the effects of CsA on
infectivity and reverse transcription, the formation
of 2-LTR circles was assessed by quantitative PCR
(qPCR) 24 hrs after transduction (Figure 3C). A primer
annealing to the 2-LTR junction was used (Figure 2B);
PCR reactions with this primer amplify only bona
fide 2-LTR circles, not the products of autointegra-
tion [26].
Relative to the amount of viral cDNA formed by either
WT or A92E, CsA increased the levels of 2-LTR circles
(Figure 3B and C). CsA increased the efficiency of nu-
clear entry, compensating for the 2-fold block in reverse
transcription of WT virus, and making the A92E CA
mutant 5-fold more infectious than it was under control
conditions in HeLa cells. The A105T CA mutant ren-
dered WT and A92E viruses insensitive to the effect of
CsA on the nuclear entry of the viral cDNA. Though the
A105T mutation prevents CypA-mediated nuclear entry
inhibition without blocking the CypA/CA interaction
[23], this CA mutant still requires CypA for optimal re-
verse transcription. Additionally, CsA increased A92E
viral 2-LTR circles in Jurkat cells to a lesser extent than
it did in HeLa cells, indicating that CypA binding to CA
inhibits HIV-1 nuclear entry to different extents in HeLa
and Jurkat T cells.
Influence of the CypA-CA interaction on HIV-1 infectivity
in a panel of cell lines
The CypA-CA interaction inhibited nuclear entry of the
A92E CA mutant to different extents in HeLa and Jurkat
T cells. To further examine the effect of CsA on A92E
transduction, 27 cell lines and primary CD4+ T cells
were treated with 5 μM CsA, or DMSO as control, and
challenged with the three-part HIV-1 vector bearing the
A92E mutation (Figure 4). 72 hrs after transduction, ex-
pression of the GFP reporter was assessed by flow cy-
tometry. As previously reported [16,17,19,21,29], A92E
infection of HeLa and H9 cells was increased signifi-
cantly when the CypA-CA interaction was disrupted
(11-fold and 6-fold, respectively, Figure 4). A92E replica-
tion was increased 7-fold by CsA in the human Burkitt’s
lymphoma derived B-cell line AKATA [36] and in the
human alveolar adenocarcinoma epithelial cell line A549
[37]. Enhancement of A92E replication by CsA was
between 2 to 4-fold in 13 cell lines tested and in the pri-
mary CD4+ T cells. Transduction of 9 cell lines was not
significantly altered by CsA. Finally, CsA inhibited A92E
virus transduction of the human T cell line MT4 [38] by
about 2-fold. The effect of CsA on A92E transduction
therefore varied over a large range in the 27 cell lines
tested (Figure 4).




Figure 2 Schematic for strategy to amplify viral cDNA and
2-LTR circles. (A) Schematic for the amplification of the final
product of reverse transcription. This PCR identifies HIV-1 cDNA
formed after the “second jump” of the reverse transcription process. (B)
Schematic for the amplification of 2-LTR circles. A forward primer span-
ning the junction LTR-LTR was used in order to discriminate 2-LTR circles
from products of autointegration. The arrows indicate the primers used
in the reaction, and the dashed lines indicate the final PCR products.
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Influence of the CypA-CA interaction on HIV-1 nuclear
entry, as assessed in a panel of cell lines
Two of the 27 cell lines tested above, AKATA and MT4
cells, were selected to assess the effect of CsA on the
synthesis and nuclear entry of HIV-1 cDNA acutely
after infection (Figure 5). AKATA and MT4 cells were
transduced with WT, A92E, or A105T viruses. GFP ex-
pression was tested 72 hrs later as a marker of viral rep-
lication (Figure 5A). The effect of CsA on transduction
of AKATA cells was similar to that in HeLa cells: WT
virus was insensitive to CsA, A92E infectivity was
enhanced, while infectivity of A105T was inhibited. In
contrast, transduction of MT4 cells by WT, A92E, or
A105T was inhibited by CsA.
The formation of late reverse transcription products
and 2-LTR circles was assessed next in AKATA and
MT4 cells treated with CsA. Reverse transcription of
WT, A92E, or A105T viruses, in the setting of acute in-
fection of either AKATA or MT4 cells was inhibited by
CsA treatment (Figure 5B). In AKATA cells treated with
CsA, WT virus infection was rescued at the level of nu-
clear entry (Figure 5C). Nuclear entry of the A92E virus
was inhibited compared to WT virus and the CsA
treatment rescued the block. Nuclear entry of none of
the tested viruses was altered significantly compared to
cDNA levels when MT4 cells were used for the analysis.
To confirm that the effect of CsA on A92E nuclear
entry resulted from CypA blockade, endogenous CypA
protein was depleted from AKATA to nearly undetect-
able levels using the lentiviral miRNA vectors (Figure 6A).
A92E transduction (Figure 6B) and nuclear entry
(Figure 6D) were enhanced by CypA KD in AKATA
cells, reproducing the phenotype seen with transduc-
tion in the presence of CsA (Figure 5).
Influence of the CypA-CA interaction on HIV-1 nuclear
import, as assessed in a panel of HeLa cell clones
A92E vector was more dependent on CsA in HeLa cells
than in any of the other 27 cell lines tested (Figure 4).
HeLa cell transduction by A92E was ~3-fold lower than
by the WT, and CsA enhanced its infectivity around 11-
fold (Figure 3A). The variable permissivity of target cells
cloned by limiting dilution [39,40] was exploited next to
obtain 32 HeLa cell clones in which the stimulation of
A92E transduction by CsA ranged from 4 to 22-fold
(Figure 7).
Figure 3 CypA promotes HIV-1 reverse transcription in both HeLa and Jurkat T cells, but inhibits nuclear entry in HeLa cells. HIV-1
reporter viruses bearing wild-type (WT) CA or the indicated CA mutants, were used to challenge HeLa (left) or Jurkat T (right) cells, treated with
5 μM CsA or DMSO as control. 72 hours later GFP expression was assessed by flow cytometry (A). 24 hrs later, late reverse transcription (B) and
2-LTR circles (C) were assayed by quantitative PCR. Data represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
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The two clones with the most extreme effects of CsA
on A92E transduction, 3D and 5C, were selected for
further testing. In the HeLa 3D clone, CsA enhanced
A92E transduction 22-fold and WT transduction 4-fold
(Figure 8A). In the HeLa 5C clone, A92E transduction
increased only 4-fold in the presence of CsA; WT virus
infectivity was not altered. A105T transduction was
inhibited in the 3D clone as in the parental HeLa cell
line but in the 5C clone the magnitude of inhibition by
CsA was reduced. HIV-1 vectors transducing HeLa 3D
and 5C clones showed stable phenotypes up to 3 months
after clone derivation (data not shown).
The efficiency of reverse transcription (Figure 8B) and
of 2-LTR circle formation (Figure 8C), after challenge of
the 3D and 5C HeLa clones with WT, A92E, and A105T
vectors, was examined next. CsA blocked the accumula-
tion of late reverse transcripts by all three vectors in
both HeLa cell clones (Figure 8B). In all cases, CsA in-
creased the level of 2-LTR circles to the same extent that
it increased transduction efficiency (Figure 8C). In the
HeLa 3D clone, even 2-LTR accumulation by the WT
vector was increased in the presence of CsA. These re-
sults indicate that CsA promotes transduction efficiency
by promoting nuclear entry of the HIV-1 pre-integration
complex.
Modulation of HIV-1 nuclear entry is not determined by
CypA protein level
Some previous studies indicate that the cells in which
CsA enhances A92E replication contain higher levels of
CypA compared to cells in which CsA has no effect on
A92E replication [15-19,29]. Other studies, offer evi-
dence that a dominant, CypA-dependent restriction
factor is expressed in the cell lines in which replication
of the A92E is CsA-dependent [16,19].
To determine whether increased amounts of CypA
protein correlates with the effects of CsA on A92E in-
fectivity, CypA protein levels were analyzed by western
blot in 3 cell lines where A92E transduction is highly
stimulated by CsA (HeLa, AKATA, and A549), 3 cell
lines where A92E transduction is moderately enhanced
(TE671, Jurkat T and W132 cells), and 2 cell lines where
A92E is inhibited by CsA (BL41 and MT4). Loading of
the gel was normalized by number of cells and by western
blot for actin. CypA protein levels varied slightly but there
was no correlation with the CsA phenotype (Figure 9A).
Similarly, no consistent difference in CypA protein levels
was observed when the 3D and 5C HeLa clones were com-
pared to each other (Figure 9B).
CypA increases HIV-1 CA core stability
Previous work has shown a role for CypA in the uncoat-
ing of HIV-1 CA cores [29,31]. Li et al. used an in vivo
assay to demonstrate that CypA either stabilizes or de-
stabilizes HIV-1 cores, depending on the specific target
cell [29]. Shah et al. showed that CypA inhibits HIV-1
CA core disassembly in vitro [31].
To assess the in vivo stability of WT and A92E CA
cores after acute infection in the presence of CsA, HeLa
clone 3D and MT4 cells were used as target cells. As
controls for conditions under which CA cores have pre-
ciously characterized stabilities, each of these cell lines was
transduced to express either human TRIM5 fused to hu-
man CypA (hT5Cyp) or a non-restrictive mutant that has
the CA binding site in CypA disrupted (hT5Cyp-H436Q)
[41]. hT5Cyp is a restriction factor modeled after the Aotus
TRIMCyp gene [39]. hT5Cyp potently restricts HIV-1 re-
verse transcription, most likely by destabilizing the HIV-1
CA core [42]. As expected, WT and A92E viruses were re-
stricted by hT5Cyp in HeLa clone 3D (Figure 10A) and in
MT4 (Figure 10B). In the case of both cell lines, disruption
Figure 4 Variable effect of CsA on transduction of different cell
lines by HIV-1 bearing the A92E CA mutant. A panel of 27 cell
lines and human CD4+ T cells were treated with 5 μM CsA or DMSO
as control and challenged with an HIV-1-GFP reporter vector bearing
the A92E CA mutation. 72 hrs post-transduction the percent GFP+
cells was determined by flow cytometry, as an indicator for infectivity.
The ratio of A92E mutant virus infectivity in CsA vs DMSO treated cells is
shown. Data represent one of at least two independent experiments.
Error bars represent ± SEM.
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of the CypA catalytic site in hT5Cyp (H436Q), mutation of
an HIV-1 CA amino acid important for interaction with
CypA (G89V), or the competitive inhibitor CsA, prevented
restriction activity (Figure 10).
HeLa clone 3D bearing hT5Cyp-H436Q was chal-
lenged with envelope-minus HIV-1 pseudotyped with
VSV G, bearing either WT or A92E CA, in the presence
of CsA or DMSO as solvent control. 16 hrs post-
transduction, cells were lysed and the cytoplasmic ex-
tract was accelerated through a 50% sucrose cushion. As
compared with WT CA, the recovery of A92E CA in the
pellet was significantly increased (Figure 11A). CsA de-
creased the amount of CA protein recovered in the pel-
let for both WT and A92E CA. hT5Cyp also decreased
the CA yield in the pellet, an effect that was reversed by
CsA to the level seen in the absence of any CypA/CA
interaction. Virus without VSV G was used as a control
for CA that had been taken up by cells non-specifically.
These results indicate that the CA-CypA interaction in-
hibits HIV-1 nuclear entry by stabilizing the virion core.
To determine if increased CA core stability also ex-
plains the increased reverse transcription due to CypA,
similar CA recovery experiments were conducted with
MT4 cells (Figure 11B); CsA decreased reverse tran-
scription in these cells without increasing nuclear entry.
In MT4 cells bearing hT5Cyp-H436Q the recovery of
A92E CA in the pellet was similar to that of the WT
CA, and CsA caused no change for either. CA recovery
was greatly decreased in MT4 cells bearing hT5Cyp, and
this effect was blocked by CsA. Additionally, identical
results were observed in the parental cells that did not
express hT5Cyp (data not shown). Thus, while effects of
CypA on nuclear entry correlated with effects of CypA
on CA core stability (Figure 11A), the effects of CypA
on reverse transcription did not correlate in any detect-
able way with effects on core stability (Figure 11B).
CsA blocks reverse transcription at 6 hrs post infection
The peak accumulation of HIV-1 full-length linear
cDNA occurs between 6 and 12 hrs post-infection [35].
Given that HIV-1 cDNA was evaluated 24 hrs after in-
fection in the above experiments, the effect of CsA was
assessed at an earlier time point to see if conclusions
were the same. HeLa 3D and MT4 cells were transduced
Figure 5 CypA promotes HIV-1 reverse transcription in both AKATA and MT4 cells, but inhibits nuclear entry in AKATA cells. HIV-1
reporter viruses bearing wild-type (WT) CA or the indicated CA mutants, were used to challenge AKATA (left) or MT4 (right) cells, treated with
5 μM CsA or DMSO as control. 72 hours later GFP expression was assessed by flow cytometry (A). 24 hrs later, late reverse transcription (B) and 2-LTR circles
(C) were assayed by quantitative PCR. Data represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
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with WT, A92E, and A105T capsid mutants in the pres-
ence or absence of CsA. 6 hrs later, the level of late re-
verse transcription products was assessed (Figure 12). In
each case, CsA treatment of the target cell resulted in a
reduction of full-length linear HIV-1 cDNA.
Discussion
Host cell CypA promotes HIV-1 reverse transcription
Previous studies showed that CypA is required for HIV-
1 replication in specific cell types, but not in others
[11,15-19]. In addition, it was shown that the require-
ment of CypA for HIV-1 was after virus entry but prior
to reverse transcription [11,16,17,29]. The experiments
reported here demonstrate that interaction between
CypA and CA is important for the completion of HIV-1
reverse transcription in cells where the CA-CypA inter-
action has no detectable effect on infectivity, or even in-
hibits it.
How CypA promotes reverse transcription remains
unclear. Li et al. showed that CypA regulates optimal
stability of the HIV-1 CA core in Jurkat T cells and
that disruption of the CypA-CA interaction results in
premature uncoating [29]. Since the process of CA core
uncoating is associated with reverse transcription, such
CA destabilization would be expected to result in the in-
hibition of virus replication [43]. However, the experi-
ments here showed that HIV-1 transduction of Jurkat T
cells was partially defective for nuclear entry in the
presence of CypA. When HIV-1 was tested on MT4
cells, the only cell line where CypA favors HIV-1 reverse
transcription without effect on nuclear entry, CsA had
no significant effect on the WT CA stability. However,
the assay for in vivo CA stability might not be sensitive
enough to detect the small block in reverse transcription
caused by CsA. Using an in vitro assay, Shah et al. detected
a stabilizing effect of CypA on HIV-1 CA [31].
CypA inhibits HIV-1 nuclear entry by promoting CA
core stability
HIV-1 carrying either A92E or G94D CA mutations
were selected by serial passage of HIV-1 on CD4+-HeLa
cells in the presence of CsA [21]. It remains unclear at
which step of the HIV-1 replication cycle CsA enhances
replication of these mutant viruses [16,17,29,30]. Using a
recently optimized PCR assay to quantify HIV-1 2-LTR
circles [23,26], it was determined here that CsA stimu-
lates replication of the A92E CA mutant, and to a lesser
extent the WT virus, at a step between the formation of
the viral cDNA and its transport into the nucleus. It was
also demonstrated that the block to nuclear entry corre-
lates with increased yield of particulate HIV-1 CA from
the cytoplasm of acutely infected cells. These results
suggest that when CypA interacts with HIV-1 CA it de-
lays virion uncoating. It was recently shown that another
cellular factor, CPSF6, can bind to HIV-1 CA, stabilize
Figure 6 The effect of CypA KD in AKATA cells on HIV-1 transduction. (A) CypA level in AKATA cells transduced with a lentiviral vector
expressing an shRNA targeting CypA, or control (Ctrl). Cell lysates were probed in western blot with antibodies against β-actin (upper panel) or
CypA (lower panel). CypA and Ctrl KD AKATA cells were challenged with WT or CA mutant HIV-1 reporter viruses. 72 hours later GFP expression
was assessed by flow cytometry (B). 24 hrs after infection, late reverse transcription (C), or 2-LTR circles (D), were assayed by quantitative PCR.
Data represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
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CA cores, and block nuclear entry of HIV-1 cDNA, in a
similar fashion [26].
A92E sensitivity to CsA is highly variable in different cells
Replication of A92E virus was previously described to be
dependent on CsA in HeLa and H9 cells, and independ-
ent from CsA in MT4, CEM, 293 T, HOS, TE671 and
Jurkat T cells [11,15-19]. Here the replication of A92E in
the presence of CsA was assessed in 8 cell lines that had
previously been characterized and in 19 additional cell
lines. Results here show that the effect of CsA on the
mutant virus was highly variable. MT4 was the only cell
line analyzed in which A92E was sensitive to the block
in reverse transcription in presence of CsA, but totally
independent of the drug at a subsequent step in the rep-
lication cycle. In contrast, A92E reverse transcription
was decreased when the CypA-CA interaction was dis-
rupted in 293 T, HOS, CEM, TE671 and Jurkat T cells,
but this block was rescued at the level of nuclear entry.
It is also interesting to note how different A92E behaves
in the presence of CsA when replicating in very similar
cell lines such as the Burkitt lymphoma B-cell lines
AKATA and BL41, or in the T-cell lines H9 and MT4.
To understand if CypA protein levels explain the
different sensitivity of A92E to CsA in different cell lines
the CypA protein levels were measured in 8 cell lines where
A92E behaved differently in presence of CsA (Figure 9).
Some slight differences in CypA expression were detectable,
but they did not correlate with the CsA-dependence in
those cell lines.
These results reinforce the hypothesis that a CypA-
dependent restriction factor is differentially expressed in
different cell lines [16,19]. Song et al. previously analyzed
heterokaryons formed by fusing CsA-dependent HeLa
cells and CsA-independent 293 T cells, and showed that
the CsA-dependence of the A92E and G94D mutants
was dominant, suggesting the presence of a cellular re-
striction factor [16]. The results here indicate that WT
HIV-1 is restricted at the level of nuclear entry in some
cell lines by an unknown restriction factor that also re-
quires CypA. Moreover, the A92E CA mutation renders
HIV-1 more sensitive to this putative restriction factor.
Are CPSF6 or MX2 the CypA-dependent restriction
factors?
Disruption of CypA-CA interaction with competitive in-
hibitors or mutation of viral CA restores the infectivity
of WT and A92E mutant viruses [22]. The A105T muta-
tion renders viruses with WT or A92E CA independent
of the restriction on nuclear entry without preventing
binding of CypA to CA [23]. A105 might prevent recog-
nition by the putative restriction factor, independently of
the CypA-CA interaction. Recently, CA mutant A105T
was described for its ability to prevent restriction of
HIV-1 replication by a truncated form of the human
protein CPSF6 [26]. Like the unknown CypA-dependent
restriction factor proposed here, CPSF6 hyperstabilizes
the HIV-1 CA core, blocking transduction at a step be-
tween reverse transcription and nuclear entry. These
effects have only been observed when CPSF6 is forced to
accumulate in the cytoplasm and have never been re-
ported with the endogenous protein under physiologic
conditions. Nonetheless, CPSF6 might be responsible for
the inhibition of HIV-1 replication prior to nuclear
entry in a CypA-dependent manner. Supporting this
idea, Shah et al. showed that CsA reduces the inhibitory
Figure 7 Variable effect of CsA on transduction of different
HeLa cell clones by HIV-1 bearing the A92E CA mutation. 32
HeLa cell clones were treated with 5 μM CsA or DMSO as control
and challenged with an HIV-1-GFP reporter vector bearing the A92E
CA mutation. 72 hrs post-transduction the percent GFP+ cells was
determined by flow cytometry, as an indicator for infectivity. The
ratio of A92E mutant virus infectivity in CsA vs DMSO treated cells is
shown. Data represent one of at least two independent experiments.
Error bars represent ± SEM.
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effect after depletion of TNPO3 [31]. Recent studies de-
scribed a new HIV-1 restriction factor, myxovirus resist-
ance 2 (MX2) [44-46]. MX2 is an interferon-induced
protein that blocks nuclear entry of HIV-1 in a CA-
dependent manner [44]. CypA depletion or mutation on
CA preventing CypA binding (G89V) prevent HIV-1 re-
striction mediated by MX2 [46]. Further analysis of the
role of CPSF6 and MX2 in CsA-treated cells is required
to determine the role these host factors in the pheno-
types reported here.
Conclusions
Since the first report in 1993 of direct binding between
HIV-1 CA and CypA, many studies have tried to
characterize the functional significance of this inter-
action. CypA was shown to influence HIV-1 reverse
transcription and later steps of viral replication in a
cell type-dependent manner, but the results were often
different in different labs. Here the mechanism of action of
CypA was revisited with improved qPCR techniques to
assess the efficiency of reverse transcription and nuclear
entry of a panel of CA mutants transducing 27 different
cell lines and 32 HeLa clones in the presence of the
CypA inhibitor CsA. CypA promoted HIV-1 reverse
transcription under all conditions, but inhibited HIV-1
nuclear entry in a cell type-dependent manner. More-
over, evidence is provided that CypA facilitates HIV-1
restriction by a dominant-acting restriction factor that
stabilizes CA cores.
Methods
Cell lines, tissue culture, primary cells, and drugs
HeLa, 293 T, TE671, W132, IMR90, CCL21, HOS,
HepG2, MRC5, MCF7 and A549 cells were grown in
Dulbecco’s modified Eagle medium (DMEM) (Invitro-
gen) supplemented with 10% fetal bovine serum (FBS)
(PAA), 20 mM L-glutamine, 1000 U/ml penicillin, and
1000 mg/ml Streptomycin (GIBCO). MT4, Jurkat T,
BL41, HUT78, AKATA, HBS-2, JM, H9, D1.1, C8166,
RAJI, RAMOS, D675 and CEM were grown in Roswell
Figure 8 The effect of CsA on transduction of HeLa cell clones 3D and 5C by HIV-1. WT or CA mutant HIV-1 reporter viruses were used to
challenge HeLa 3D (left) or 5C (right) clones treated with 5 μM CsA or DMSO as control. 72 hours later GFP expression was assessed by flow
cytometry (A). 24 hours later, late reverse transcription (B) and 2-LTR circles (C) were assayed by quantitative PCR. Data represent one of at least
three independent experiments. Error bars represent ± SEM (n = 3).
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Park Memorial Institute medium (RPMI) (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (PAA),
20 mM L-glutamine, 1000 U/ml penicillin, and 1000 mg/
ml Streptomycin (GIBCO). Human CD4+ Tcells were puri-
fied by EasySep CD4+ T Cell Enrichment Kit (StemCell
Technologies) and cultured in X-Vivo 15 medium (Lonza)
in the presence of IL-2 (30 U/ml). Transduction with lenti-
viral vectors was performed 3 days after stimulation with
Dynabeads human T-activator CD3/CD28 (Lifetechnolo-
gies). Cyclosporine A (CsA, Sigma-Aldrich) was used at a
concentration of 5 μM.
Plasmids
pWPTs-GFP is an HIV-1-based transfer vector with EGFP
expression under the control of the EF1α promoter [47].
p8.9NdSB is a minimal HIV-1 packaging plasmid for gag
and pol expression. p8.9NdSB bearing G89V, G89V/A92E,
P90A, P90A/A92E, A92E, A92E/A105T and A105T in the
CA sequence were previously described [23]. pMD2-G
encodes the vesicular stomatitis virus G protein (VSV-G)
[48]. pAPM is an HIV-1 based knockdown vector in
which a single transcript driven by the spleen focus-
A 
B 
Figure 10 Effect of hT5Cyp on HIV-1 transduction. HeLa clone 3D (A) and MT4 cells (B), stably expressing the WT or mutated (H436Q)
hT5Cyp restriction factor, were treated with CsA or DMSO as control, and challenged with HIV-1-GFP reporter viruses bearing WT, G89V or A92E
mutant capsid. Expression of GFP was checked by flow cytometry 72 hrs after challenge with the virus. Infectivity relative to WT virus is represented. Data
represent one of at least three independent experiments. Error bars represent ± SEM (n = 3).
A
B





HeLa AKA JUR MT4
Actin
A549 TE671 BL41W132
Figure 9 CypA protein level in different cell lines does not
correlate with CsA-dependency. CypA protein levels by western
blot in HeLa, AKATA (AKA), A549, TE671, Jurkat T (JUR), W132, BL41
and MT4 cell lines (A), and in HeLa 3D and 5C clones (B). Loading
was normalized by cell count. In B, samples were serially diluted
4-fold. Cell lysates were probed in western blots with anti-CypA
antibody (upper panel) and anti-β-actin antibody (lower panel).
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forming virus (SFFV) LTR contains a miR30 framework
modified to target a gene of interest and the puromycin
N-acetyltransferase gene [33]. pAPM-CypA and pAPM-
control were used to knock-down respectively CypA or
control mRNA [49]. hT5Cyp and hT5Cyp-H436Q viral vec-
tors were previously described [41].
Production of viruses and vectors
Viruses and minimal vectors were produced by transfec-
tion of 293 T cells using Polyethylenimine (PEI) (Sigma,
Inc), and normalized for reverse transcriptase activity
(SGPERT) [23].
Reverse transcriptase assay (SGPERT)
Reverse transcriptase activity in the supernatants was
quantified using a Sybr green I-based real-time PCR
enhanced reverse transcriptase assay (SGPERT) that
possesses both high sensitivity and an extraordinary dy-
namic range [23]. The assay is a modified version of
one described previously [50]. Briefly, virions in cell-free
supernatant were disrupted by adding an equal volume of
SGPERT lysis buffer containing 0.25% Triton X-100,
50 mM KCl, 100 mM TrisHCl pH7.4, 0.4 U/μl RNase in-
hibitor (RiboLock, MBI Fermentas). Lysed virions were
used for reverse transcription of MS2 RNA template
(Roche) [51]. Quantification of reverse transcribed prod-
ucts was carried out in a CFX96 thermal cycler
(Biorad) using Sybr-Green I, hotstart Taq and reaction
buffer (Fermentas), and an MS2 primer set as already
described [51]. A standard curve was obtained using
known concentrations (expressed in functional units)





HIV-1: WT CA A92E CA NoVSV G
−hT5Cyp: − + + −− −
− + − +− +CsA:
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−
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Figure 11 The CypA-CA interaction hyper-stabilizes HIV-1 CA cores in a target cell-specific fashion. env-minus HIV-1, pseudotyped with
VSV G, and bearing either WT or A92E mutant CA, was incubated with HeLa clone 3D (A) or MT4 cells (B) stably expressing hT5Cyp or hT5Cyp-
H436Q, as indicated. Cells were treated with CsA or DMSO as control, for 16 hrs. As a control, to demonstrate, that signals in this assay required
viral entry, virions lacking VSV G were used. The target cells were lysed and the cytoplasmic fraction (input) was pelleted through a 50% sucrose
cushion to obtain the particulate fraction (pellet). The fractions were then analyzed by western blot with anti-p24 antibody. All experiments are
representative of at least 2 repetitions.
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Generation of stable KD cell lines
HeLa, Jurkat T and AKATA cells were transduced with
pAPM microRNA-based shRNA vectors targeting either
control or CypA mRNA. Cells were selected with 2 to
10 μg/mL of puromycin two days after transduction.
Western blot analysis
For western blot analysis we used rabbit anti-CypA anti-
body (Enzo Life Sciences), human anti-p24 (NIBSC) and
mouse anti-actin antibody (Sigma). The secondary anti-
bodies were HRP-linked donkey anti-rabbit IgG (GE
Healthcare Life Sciences), HRP-linked donkey anti-human
IgG (Jackson) and HRP-linked sheep anti-mouse IgG (GE
Healthcare Life Sciences).
Quantitative PCR for late reverse transcriptase products
and 2-LTR circles
Low molecular weight DNA was extracted from 4 × 106
cells using the QIAprep Spin Miniprep Kit (Qiagen), fol-
lowing the manufacturer’s instructions. Late RT analysis
was previously described [23].
The primers used for the 2-LTR circle detection are:
Junct2 fwd, 5′- CAGTGTGGAAAATCTCTAGCAGT
AC-3′ [44], coupled with pWPT J2 rev, 5′-GCCGTG
CGCGCTTCAGCAAGC-3′ [23]. 2-LTR circles qPCRs
with TaqMan probe detection method were made using
the primers (Butler 2001): MH535, 5′-AACTAGGGA
ACCCACTGCTTAAG-3′; and MH536. 2-LTR circle
PCR reaction mix contained 1× Sybr green mix (10 mM
Tris pH 8.3, 10 mM KCl, 2.5 mM NH4SO4, 5 mM
MgCl2, 0.1 mg/ml BSA, 0.2 mM dNTPs, 1x Sybr green),
300 nM each primer, 6 μl of template low-molecular
weight DNA, and 0.2 μl of Hot Start Taq Polymerase
(Promega) in a volume of 20 μl. After initial incubation
at 95°C for 2 min to activate the Hot Start Taq Polymer-
ase, 40 cycles of amplification and acquisition were car-
ried out at 95°C for 6 s, followed by 10 s at 55°C, 30 s at
72°C and 6 s at 80°C.
Where indicated, cells were treated 1 hour before
infection with 5 μM CsA.
Fate of capsid assay
Fate of capsid assay was performed as previously de-
scribed [44]. Hela clone 3D and MT4 cells expressing
hT5Cyp or hT5Cyp-H436Q were seeded onto T75 flasks.
24 hours later, the confluent cells were incubated with
10 ml of Env- HIV-1, pseudotyped with VSV G, and
bearing either WT or A92E mutant CA, in presence of
5 μM CsA for 30 min at 4°C and then shifted to 37°C.
After 4 hours, the virus was removed, the cells were
washed and returned to 37°C in presence of 5 μM CsA
for 12 hours. Cells were detached with pronase (7 mg/
ml in DMEM) for 5 min at 4°C, washed 3 times with ice
cold PBS and finally resuspended in 2.5 ml of hypotonic
lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM KCl,
1 mM EDTA). After 5 min incubation on ice, the cells
were lysed in a 7-ml Dounce homogenizer by 15 stokes
with pestle B. The lysate was cleared by centrifugation
for 3 min at 3,000 rpm at 4°C to remove the nuclear
fraction. 100 μl of the cleared lysate was collected to de-
termine the viral input in the assay, while 2 ml was
layered on top of a 7-ml 50% sucrose gradient and
centrifuged for 2 hours at 30,000 rpm at 4°C using a
Beckman SW41 rotor. After centrifugation, the pellet was
resuspended in 1× SDS-PAGE loading buffer. Samples were
analyzed by WB using antibody against p24.
Single-cell cloning
HeLa cells were trypsinized and counted. Cells were
seeded in 96 well plates such that there was one cell per
every 5 wells. Growth of isolated clones was checked by
bright field microscopy.
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